Literature DB >> 6239688

The isolation of immunogenic molecular entities from immunogenic and nonimmunogenic tumor homogenates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

R Sharon, D Naor.   

Abstract

YAC, a Moloney-virus-induced tumor of A-strain mice, is a nonimmunogenic tumor. Mice injected with the inactivated neoplastic cells and challenged with viable tumor cells did not survive longer than mice that received the challenge dose alone. The homogenate of this nonimmunogenic tumor was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the gel slices containing isolated molecular entities were injected into various groups of mice. The mice were challenged with low doses of viable tumor cells (10-30 cells) and their survival time was recorded. Small but significant numbers of mice injected with apparent 80-90 K SDS-PAGE-isolated molecular entity rejected the tumor or survived longer than the control groups of mice. Spleen cells from mice injected with 80-90 K molecular entity inhibited the YAC tumor cotransferred with them to naive recipients (Winn assay). Spleen cells from mice injected with monoclonal antibody against nonspecific T-cell helper factor and immunized with 80-90 K SDS-PAGE-isolated molecular entity failed to inhibit the tumor growth in naive recipients, indicating that helper T cells are involved in induction of the antitumor resistance. Nylon-wool-passed splenocytes from mice injected with 80-90 K inhibited tumor growth in some of the recipient mice. Spleen cells from these mice treated with anti-Thy-1 and complement also inhibited the tumor growth in some of the recipients, suggesting that the effector cells were both T and non-T cells. C57BL/6 mice immunized with apparent 20 K SDS-PAGE-isolated molecular entity of RBL5 tumor also induced in vivo resistance to the syngeneic viable RBL5 cells, but not to the syngeneic B16 melanoma cells, indicating the specificity of the protective effect. The practical and theoretical implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239688     DOI: 10.1007/bf00205512

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  The immune response and the homograft reaction.

Authors:  H J WINN
Journal:  Natl Cancer Inst Monogr       Date:  1960-03

Review 2.  The role of antigen-specific T cell factors in the immune response.

Authors:  T Tada; K Okumura
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

Review 3.  Suppressor cells: permitters and promoters of malignancy?

Authors:  D Naor
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

4.  Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus.

Authors:  G Klein; E Klein; G Haughton
Journal:  J Natl Cancer Inst       Date:  1966-04       Impact factor: 13.506

5.  Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine.

Authors:  I J Fidler
Journal:  J Natl Cancer Inst       Date:  1970-10       Impact factor: 13.506

Review 6.  Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules.

Authors:  D Naor
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Comparative studies on the induction of transplantation resistance in BALB-c and C57BL-6 mice in three murine leukemia systems.

Authors:  J L McCoy; A Fefer; J P Glynn
Journal:  Cancer Res       Date:  1967-10       Impact factor: 12.701

8.  Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. I. Screening of immunogenic components by isopycnic ultracentrifugation and polyacrylamide electrophoresis of a tumor homogenate.

Authors:  B Y Klein; S Frenkel; A Ahituv; D Naor
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Reduction of syngeneic tumor growth by an anti-I-J-alloantiserum.

Authors:  M I Greene; M E Dorf; M Pierres; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  Immune responses to weakly immunogenic virally induced tumors. I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross-reactive tumor.

Authors:  N Galili; B Devens; D Naor; S Becker; E Klein
Journal:  Eur J Immunol       Date:  1978-01       Impact factor: 5.532

View more
  4 in total

1.  Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

Authors:  S L Hu; G D Plowman; P Sridhar; U S Stevenson; J P Brown; C D Estin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.

Authors:  M Hareuveni; C Gautier; M P Kieny; D Wreschner; P Chambon; R Lathe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Authors:  C D Estin; U S Stevenson; G D Plowman; S L Hu; P Sridhar; I Hellström; J P Brown; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

4.  A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B.

Authors:  Aniuska Becerra-Artiles; Omar Dominguez-Amorocho; Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.